Cite
MLA Citation
Lorraine Pelosof et al.. “Benefit–Risk Summary of Nivolumab for the Treatment of Patients with Unresectable Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma After Prior Fluoropyrimidine‐ and Platinum‐Based Chemotherapy.” Oncologist, vol. 26, 2021, pp. 318–324. http://access.bl.uk/ark:/81055/vdc_100124386399.0x00003b